Anagrelide is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
FDA,2021.10
Anagrelide is used to reduce the platelet count in patients with myeloproliferat···【more】
Release date:2026-01-30Recommended:39
Thrombocythemia【more】
Release date:2026-01-05Recommended:30
LuciusVersionofAnagrelide:DosageandAdministration,Indications,PrecautionsIndicat···【more】
Release date:2025-12-02Recommended:83
Anagrelide is a drug used to treat thrombocythemia, primarily for abnormal eleva···【more】
Release date:2024-12-12Recommended:228